Jennison holds 1.71M shares in TARSUS PHARMACEUTICALS (TARS) — 4.0%

Rhea-AI Filing Summary

TARSUS PHARMACEUTICALS INC Schedule 13G/A amendment reports that Jennison Associates LLC beneficially owns 1,712,124 shares of common stock, representing 4.0% of the class. The filing lists sole voting power for 1,712,124 shares and shared dispositive power for 1,712,124 shares.

Key Figures

Shares beneficially owned: 1,712,124 shares Percent of class: 4.0% CUSIP: 87650L103 +2 more

5 metrics

Shares beneficially owned 1,712,124 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 4.0% Percent of class reported in Item 4(a)/(b)

CUSIP 87650L103 CUSIP for TARS common stock listed on cover

Report date 03/31/2026 Date appearing near cover information

Signature date 05/06/2026 Date the filing was signed by Jennison Compliance officer

Key Terms

Schedule 13G/A, beneficially owned, sole voting power, shared dispositive power

4 terms

Schedule 13G/A regulatory

"Schedule 13G/A (Amendment No. 1) reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: 1712124 (b) Percent of class: 4.0 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power regulatory

"Sole power to vote or to direct the vote: 1712124"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power regulatory

"Shared power to dispose or to direct the disposition of: 1712124"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What stake does Jennison Associates report in TARS (TARSUS PHARMACEUTICALS)?

Jennison Associates reports beneficial ownership of 1,712,124 shares (4.0%). The Schedule 13G/A lists 1,712,124 shares and a 4.0% ownership percentage, with the filing dated 03/31/2026 and signed on 05/06/2026.

Does Jennison Associates have voting or disposition control over the TARS shares?

Jennison Associates has sole voting power for 1,712,124 shares and shared dispositive power for 1,712,124 shares. The filing specifies sole power to vote and shared power to dispose for the same 1,712,124-share amount.

What form was filed to disclose Jennison's holdings in TARS?

The filing is a Schedule 13G/A (Amendment No. 1) for TARSUS PHARMACEUTICALS INC. It amends the beneficial ownership report and provides updated voting and dispositive power figures as of 03/31/2026.

What CUSIP and issuer address appear on the filing for TARS?

The filing lists CUSIP 87650L103 and issuer address 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618. These identifying details appear in Item 1 and the cover information on the Schedule 13G/A.

Who signed the Schedule 13G/A amendment for Jennison Associates and when?

The Schedule 13G/A is signed by Beata Markowicz, Senior Vice President, Compliance. The signature block shows the signing date as 05/06/2026, following the reporting date 03/31/2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

TARSUS PHARMACEUTICALS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

87650L103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 87650L103

1

Names of Reporting Persons

Jennison Associates LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,712,124.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,712,124.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,712,124.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TARSUS PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618
Item 2.
(a)	Name of person filing: Jennison Associates LLC
(b)	Address or principal business office or, if none, residence: 55 East 52nd Street, New York, NY 10055
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 87650L103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1712124
(b)	Percent of class: 4.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1712124
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1712124
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Jennison Associates LLC

Signature:	Beata Markowicz
Name/Title:	Senior Vice President, Compliance
Date:	05/06/2026